Brief: Matinas Biopharma Holdings Says Under Agreement With Biontech, Co Will Receive Exclusivity Fee Of $2.75 Mln
11/04/2022 12:16
April 11 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA HOLDINGS- UNDER TERMS OF COLLABORATION
AGREEMENT WITH BIONTECH, CO WILL RECEIVE EXCLUSIVITY FEE IN THE
AMOUNT OF $2.75 MILLION
Further company coverage: MTNB.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing